VENTOLIN Drug Patent Profile

Which patents cover Ventolin, and what generic alternatives are available?

Ventolin is a drug marketed by Glaxosmithkline and is included in seven NDAs.

The generic ingredient in VENTOLIN is albuterol sulfate. There are thirty-eight drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the albuterol sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ventolin

A generic version of VENTOLIN was approved as albuterol sulfate by SUN PHARM INDUSTRIES on December 5^th, 1989.

Summary for VENTOLIN

US Patents:	0
Applicants:	1
NDAs:	7

US Patents and Regulatory Information for VENTOLIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	VENTOLIN	albuterol	AEROSOL, METERED;INHALATION	018473-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Glaxosmithkline	VENTOLIN HFA	albuterol sulfate	AEROSOL, METERED;INHALATION	020983-001	Apr 19, 2001	BX	RX	Yes	Yes
Glaxosmithkline	VENTOLIN	albuterol sulfate	SYRUP;ORAL	019621-001	Jun 10, 1987		DISCN	No	No
Glaxosmithkline	VENTOLIN ROTACAPS	albuterol sulfate	CAPSULE;INHALATION	019489-001	May 4, 1988		DISCN	No	No
Glaxosmithkline	VENTOLIN	albuterol sulfate	SOLUTION;INHALATION	019773-001	Apr 23, 1992		DISCN	Yes	No
Glaxosmithkline	VENTOLIN	albuterol sulfate	SOLUTION;INHALATION	019269-002	Jan 16, 1987		DISCN	No	No
Glaxosmithkline	VENTOLIN	albuterol sulfate	TABLET;ORAL	019112-002	Jul 10, 1986		DISCN	No	No

International Patents for VENTOLIN

See the table below for patents covering VENTOLIN around the world.

Country	Patent Number	Title	Estimated Expiration
Ireland	34326	PHENYLAMINOETHANOL DERIVATIVES
Belgium	704037
Malaysia	7500140	PHENYLAMINOETHANOL DERIVATIVES
Switzerland	656308	COMPOSITIONS PHARMACEUTIQUES CONTENANT DU SALBUTAMOL.
Austria	390191
Philippines	19601	PHARMACEUTICAL COMPOSITIONS
Denmark	429375

Ventolin (Albuterol) Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary
Ventolin (albuterol) remains a dominant bronchodilator used for managing asthma and chronic obstructive pulmonary disease (COPD). Its market position, driven by robust demand, regulatory status, and ongoing pipeline innovations, offers notable investment opportunities. This report analyzes the current market dynamics, future growth trajectories, and key financial factors influencing Ventolin’s investment landscape.

---

What Is Ventolin and How Does It Function in the Market?

Attribute	Details
Generic Name	Albuterol (also known as salbutamol)
Brand Name	Ventolin (primarily in the US and Canada), Ventolin HFA, Ventolin Diskus (globally)
Therapeutic Class	Short-acting beta-2 adrenergic receptor agonist (SABA)
Mechanism of Action	Bronchodilation via relaxation of bronchial smooth muscle

Market Ownership

• Manufacturers: Pfizer, GlaxoSmithKline (GSK), and generic producers worldwide.
• Patent Status:
  • Original patents have expired globally, leading to widespread generic availability.
  • Some formulations (like inhalers) are still under regulatory exclusivities, especially in certain jurisdictions.

Regulatory Status

• FDA: Approved for asthma and COPD management.
• EMA: Approved similarly across European markets.
• Global Reach: Approved in over 150 countries, with varying formulations and delivery devices.

---

Market Dynamics of Ventolin: Current Trends and Future Outlook

1. Market Demand and Usage Trends

Aspect	Observation	Data/Source
Global Asthma Prevalence	Estimated 262 million people affected globally (WHO, 2021).	[1]
Chronic Obstructive Pulmonary Disease (COPD)	Expected CAGR of 4.2% till 2030, with COPD affecting over 400 million people worldwide.	[2]
Inhalation Device Preference	Metered-dose inhalers (MDIs) like Ventolin HFA dominate due to ease of use and rapid onset.	[3]
Rising Disease Burden in LMICs	Increased demand driven by urbanization and pollution.	[4]

2. Regulatory and Patent Influence

Aspect	Impact	Current Status
Patent Expiry	Leads to generic entry, decreasing price and profit margins for branded Ventolin.	Most patents expired by 2015 globally; generics prevalent.
Regulatory Exclusivities	Provide temporary market protection for specific formulations or delivery systems.	Expires variably, extending some market advantages for innovative inhalers.
Potential Patent Challenges	Patent disputes or new device patents can impact market exclusivity.	Active in jurisdictions like US and EU.

3. Competitive Landscape

Competitors	Products	Market Share	Notes
Generic Manufacturers	Multiple, including Teva, Mylan, and Sun Pharma	60-70%	Price-sensitive segment.
Brand Manufacturers (e.g., Pfizer, GSK)	Ventolin HFA and Diskus	20-30%	Premium pricing, targeted at specific markets.
Innovations & Competition	New inhaler technologies, combination therapies.		Ongoing R&D investments.

4. Technological and Product Innovation

Innovation	Objective	Current Status
Smart Inhalers	Improve adherence, real-time monitoring.	Early-stage adoption.
Combination Formulations	Ventolin with corticosteroids, or long-acting beta-agonists (LABAs).	Approved in select markets.
Alternative Delivery Devices	Dry powder inhalers (DPIs), soft mist inhalers.	Gaining market share.

---

Financial Trajectory of Ventolin: Revenue, Pricing, and Investment Considerations

1. Revenue Analysis

Market Segment	Estimated 2022 Revenue	Real Growth Rate	Notes
US	~$1.2 billion	2-3% CAGR (post-patent expiry)	Dominance in emergency and maintenance markets.
Europe	~$800 million	1.5-2% CAGR	Fragmented with multiple generics.
Emerging Markets	~$500 million	4-6% CAGR	Driven by increased access and urban pollution.
Total Global	~$2.5 billion	Steady growth, slight decline in branded revenue	Decline due to generics, offset by volume.

2. Pricing Trends

Period	Price Trend	Influencers	Impact
Pre-Patent Expiry (2000-2015)	Stable, premium pricing	Patent protection	High margins sustained.
Post-Patent Expiry (2016 onwards)	Price erosion by generics	Increased competition	Profit margins compressed.
Current Average Price per Inhaler (US)	~$30 (branded) vs. ~$8 (generics)	Market segmentation	Significant downward pressure.

3. Cost & Investment Outlook

Aspect	Details
R&D expenditure	~$100 million annually for inhaler innovation (industry average).
Manufacturing Costs	Estimated at 20-30% of retail price.
Market Entry Barriers	Stringent regulatory requirements, patent landscapes, device integration.

4. Investment Opportunities & Risks

Opportunity	Rationale	Risks
Branding & Differentiation	Innovation in inhaler design and adherence tools.	Rapid patent expiration; price erosion.
Emerging Markets Growth	Underpenetrated markets with increasing demand.	Regulatory hurdles, pricing controls.
Pipeline Expansions	Development of combination therapies, long-acting formulations.	Regulatory delays, clinical trial failures.

---

Comparative Analysis: Ventolin vs. Key Competitors

Parameter	Ventolin (Albuterol)	Tiotropium (Spiriva)	Salmeterol (Serevent)	Formulation Type
Primary Use	Rescue inhaler	Maintenance for COPD/asthma	Long-acting for maintenance	Inhalers, DPIs
Market Share (Global)	~20-30% (branded + generics)	~15-20%	~10-15%	Various
Patent Status	Expired	Patents valid till ~2024	Patents expired	Open
Pricing	$8-$30 (generics vs. branded)	$350+	$150+	Various

---

Market Opportunities and Challenges

Opportunities	Challenges
Growing asthma and COPD prevalence	Price sensitivity and insurance coverage issues.
Innovations in inhaler devices	Need for regulatory approval for new devices.
Digital health integration	Data privacy concerns.
Expansion into emerging markets	Weak healthcare infrastructure.

---

FAQs

Q1: What is the current patent status of Ventolin?
A: Most patents expired globally by 2015, leading to widespread generic availability, although some device-specific patents may still be active locally.

Q2: How are generic competitors impacting Ventolin’s market share?
A: Generics have significantly reduced prices and eroded profit margins, with generics capturing approximately 60-70% of the market.

Q3: What future innovations could influence Ventolin’s market?
A: Smart inhalers for adherence, combination therapies with corticosteroids, and novel delivery devices could reshape competitive dynamics.

Q4: Which regions offer the highest growth potential for Ventolin?
A: Emerging markets in Asia, Africa, and Latin America, driven by increasing disease prevalence and healthcare access expansion.

Q5: What regulatory trends could affect Ventolin's market?
A: Stricter inhaler labeling standards, environmental regulations reducing propellant use, and approval processes for new device formulations.

---

Key Takeaways

• Market Saturation & Competition: Post-patent expiry, Ventolin faces significant price competition from generics, with margins compressed but volume-driven demand stabilizing revenue.

• Growth Drivers: Increasing prevalence of respiratory diseases, particularly in emerging markets, coupled with device innovation, present growth prospects.

• Innovation & Pipeline Development: Investment in smart inhalers, combination therapies, and patient adherence solutions are critical for maintaining competitive advantage.

• Regulatory and Patent Dynamics: Patent expiries can substantially impact profitability, making strategic timing of product development and device innovation essential.

• Investment Outlook: While near-term revenue pressures exist due to generic competition, long-term growth potential remains via innovation, market expansion, and strategic partnerships.

---

References

[1] World Health Organization, "Global Asthma Report 2021."
[2] Grand View Research, "COPD Therapeutics Market Size & Trends."
[3] IQVIA, "Inhaler Market Report," 2022.
[4] The Lancet, "Respiratory Disease Burden in LMICs," 2020.